Alx Oncology Holdings (ALXO) - Net Assets
Based on the latest financial reports, Alx Oncology Holdings (ALXO) has net assets worth $151.35 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($178.33 Million) and total liabilities ($26.98 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ALXO goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $151.35 Million |
| % of Total Assets | 84.87% |
| Annual Growth Rate | 16.07% |
| 5-Year Change | -92.84% |
| 10-Year Change | N/A |
| Growth Volatility | 31.13 |
Alx Oncology Holdings - Net Assets Trend (2018–2025)
This chart illustrates how Alx Oncology Holdings 's net assets have evolved over time, based on quarterly financial data. See ALXO defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Alx Oncology Holdings (2018–2025)
The table below shows the annual net assets of Alx Oncology Holdings from 2018 to 2025. For live valuation and market cap data, see ALXO market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $25.98 Million | -77.13% |
| 2024-12-31 | $113.62 Million | -40.11% |
| 2023-12-31 | $189.71 Million | -27.99% |
| 2022-12-31 | $263.46 Million | -27.43% |
| 2021-12-31 | $363.05 Million | -15.54% |
| 2020-12-31 | $429.85 Million | +155840.94% |
| 2019-12-31 | $-276.00K | -103.01% |
| 2018-12-31 | $9.15 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Alx Oncology Holdings 's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 66927800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $54.00K | 0.21% |
| Other Comprehensive Income | $28.00K | 0.11% |
| Other Components | $748.72 Million | 2881.78% |
| Total Equity | $25.98 Million | 100.00% |
Alx Oncology Holdings Competitors by Market Cap
The table below lists competitors of Alx Oncology Holdings ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Smart Sand Inc
NASDAQ:SND
|
$205.90 Million |
|
China Rare Earth Holdings Limited
F:RAE
|
$205.94 Million |
|
JINSUNG T.E.C. Inc
KQ:036890
|
$206.00 Million |
|
TRG Latin America Acquisitions Corp. Class A Ordinary Shares
NASDAQ:TRGS
|
$206.07 Million |
|
Bank Amar Indonesia
JK:AMAR
|
$205.83 Million |
|
HomeChoice Investments Ltd
JSE:HIL
|
$205.79 Million |
|
Shanghai Jinqiao Export Processing Zone Development Co Ltd B
SHG:900911
|
$205.77 Million |
|
Taisol Electronics Co Ltd
TW:3338
|
$205.71 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Alx Oncology Holdings 's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 113,618,000 to 25,981,000, a change of -87,637,000 (-77.1%).
- Net loss of 101,695,000 reduced equity.
- Share repurchases of 24,000 reduced equity.
- Other comprehensive income decreased equity by 247,000.
- Other factors increased equity by 14,329,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-101.69 Million | -391.42% |
| Share Repurchases | $24.00K | -0.09% |
| Other Comprehensive Income | $-247.00K | -0.95% |
| Other Changes | $14.33 Million | +55.15% |
| Total Change | $- | -77.13% |
Book Value vs Market Value Analysis
This analysis compares Alx Oncology Holdings 's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.16x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 3.67x to 3.16x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $0.42 | $1.53 | x |
| 2019-12-31 | $-0.01 | $1.53 | x |
| 2020-12-31 | $10.79 | $1.53 | x |
| 2021-12-31 | $9.01 | $1.53 | x |
| 2022-12-31 | $6.47 | $1.53 | x |
| 2023-12-31 | $4.41 | $1.53 | x |
| 2024-12-31 | $2.18 | $1.53 | x |
| 2025-12-31 | $0.48 | $1.53 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Alx Oncology Holdings utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -391.42%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.27x
- Recent ROE (-391.42%) is below the historical average (-103.17%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -149.98% | -664.30% | 0.19x | 1.22x | $-14.65 Million |
| 2019 | 0.00% | -401.23% | 0.45x | 0.00x | $-19.22 Million |
| 2020 | -10.64% | -3869.71% | 0.00x | 1.01x | $-88.72 Million |
| 2021 | -22.99% | 0.00% | 0.00x | 1.05x | $-119.77 Million |
| 2022 | -46.87% | 0.00% | 0.00x | 1.16x | $-149.83 Million |
| 2023 | -84.76% | 0.00% | 0.00x | 1.28x | $-179.78 Million |
| 2024 | -118.69% | 0.00% | 0.00x | 1.30x | $-146.21 Million |
| 2025 | -391.42% | 0.00% | 0.00x | 2.27x | $-104.29 Million |
Industry Comparison
This section compares Alx Oncology Holdings 's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $27,896,581
- Average return on equity (ROE) among peers: -64.77%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Alx Oncology Holdings (ALXO) | $151.35 Million | -149.98% | 0.18x | $205.88 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $85.57 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $4.06 Million | -282.32% | 0.21x | $328.21 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $70.43 Million | -172.28% | 0.74x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $35.44 Million | -26.32% | 0.18x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $-1.46 Million | 0.00% | 0.00x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.90 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $67.16 Million | -67.08% | 0.33x | $3.66 Billion |
About Alx Oncology Holdings
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collabora… Read more